Search results
Showing 16 to 30 of 30 results for nintedanib
In development [GID-TA11480] Expected publication date: TBC
In development [GID-TA11432] Expected publication date: 02 July 2025
In development [GID-TA11289] Expected publication date: TBC
In development [GID-TA11140] Expected publication date: 23 July 2025
Nintedanib for untreated malignant pleural mesothelioma [ID1424]
Discontinued [GID-TA10359]
Nintedanib for treating interstitial lung disease caused by systemic sclerosis [ID1420]
Discontinued [GID-TA10427]
Nintedanib for previously treated metastatic colorectal cancer [ID1030]
Discontinued [GID-TA10138]
Evidence-based recommendations on amivantamab (Rybrevant) for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy in adults.
Find out more about NICE's new proportionate approach to technology appraisals
Osimertinib for treating EGFR T790M mutation-positive advanced non-small-cell lung cancer (TA653)
Evidence-based recommendations on osimertinib (Tagrisso) for treating epidermal growth factor receptor (EGFR) T790M mutation-positive locally advanced or metastatic non-small-cell lung cancer (NSCLC) in adults.
Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer (TA654)
Evidence-based recommendations on osimertinib (Tagrisso) for untreated locally advanced or metastatic epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer in adults.
Show all sections
Nintedanib for treating fibrosing interstitial lung disease in people aged 6 to 17 [ID6194]
In development [GID-TA11126] Expected publication date: TBC
The NICE real-world evidence framework aims to improve the quality of real-world evidence informing our guidance. The framework does not set minimum standards for the acceptability of evidence. The framework is mainly targeted at those developing evidence to inform NICE guidance. It is also relevant to patients, those collecting data, and reviewers of evidence
Show all sections
- Overview
- Introduction to real-world evidence in NICE decision making
- Conduct of quantitative real-world evidence studies
- Assessing data suitability
- Methods for real-world studies of comparative effects
- Appendix 1 - Data Suitability Assessment Tool (DataSAT)
- Appendix 2 - Reporting on methods used to minimise risk of bias
- Appendix 3 - Reporting information for selected analytical methods
Targeted treatment for rare form of aggressive lung cancer gets NICE approval
Mobocertinib recommended as a treatment for a rare and aggressive form of lung cancer
NICE chronic lung disease treatment decision could benefit 5,200 people
NICE broadens nintedanib recommendation on chronic lung disease treatment.